Jeffrey A. Meyerhardt, MD of Dana Farber Cancer Institute gives an overview of the outcomes of the randomized phase 2 study in BRAF mutated patients with colorectal cancer at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Randomized Phase 2 Study in BRAF Mutated CRC Patients
